Get the Stockscreener App
18.51
4.11%
0.73
After Hours:
17.01
-1.50
-8.10%
Bicara Therapeutics Inc stock is traded at $18.51, with a volume of 948.47K.
It is up +4.11% in the last 24 hours and up +59.29% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$17.78
Open:
$18.55
24h Volume:
948.47K
Relative Volume:
2.31
Market Cap:
$1.01B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.66%
1M Performance:
+59.29%
6M Performance:
+71.87%
1Y Performance:
-4.64%
1-Day Range:
$17.46
$19.71
1-Week Range:
$17.46
$19.71
52-Week Range:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
18.51 | 971.01M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Key facts: Merck reports $63.62B revenue; Bicara gains FDA breakthrough - TradingView
Is Bicara Therapeutics Inc. stock resilient to inflationPortfolio Profit Report & Long-Term Growth Plans - newser.com
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC - MarketScreener
Is Bicara Therapeutics Inc. stock a buy before product launchesJuly 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Bicara stock jumps after FDA grants breakthrough therapy status By Investing.com - Investing.com Nigeria
Bicara stock jumps after FDA grants breakthrough therapy status - Investing.com
Bicara Therapeutics Says Potential Head, Neck Cancer Drug Gets FDA Breakthrough Therapy Designation - MarketScreener
Bicara Therapeutics climbs after FDA's 'breakthrough' tag for cancer therapy - TradingView
Bicara Therapeutics Inc. stock chart pattern explainedWeekly Stock Report & High Accuracy Trade Alerts - newser.com
Why Bicara Therapeutics Is Rising In Pre-market? - Nasdaq
FDA grants breakthrough therapy status to Bicara’s cancer drug - Investing.com
Bicara Therapeutics Announces Ficerafusp Alfa Granted - GlobeNewswire
How to build a custom watchlist for Bicara Therapeutics Inc.Weekly Trade Recap & Intraday High Probability Alerts - newser.com
Ivan Hyep Sells 6,415 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Insider David Raben Sells 22,000 Shares - MarketBeat
Hyep Ivan, CFO of Bicara Therapeutics, sells $116k in shares By Investing.com - Investing.com Australia
Hyep Ivan, CFO of Bicara Therapeutics, sells $116k in shares - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 18,244 Shares - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $715,176.00 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 10,900 Shares - MarketBeat
Ivan Hyep Sells 6,514 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 5,627 Shares of Stock - MarketBeat
Risk adjusted return profile for Bicara Therapeutics Inc. analyzedJuly 2025 Selloffs & Breakout Confirmation Trade Signals - newser.com
Can Bicara Therapeutics Inc. stock resist sector downturnsWeekly Stock Report & Risk Managed Investment Strategies - newser.com
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares By Investing.com - Investing.com South Africa
Bicara therapeutics president Cohlhepp sells $911k in shares - Investing.com
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares - Investing.com
Bicara therapeutics president Cohlhepp sells $911k in shares By Investing.com - Investing.com UK
Day 8 of Gains Streak for Bicara Therapeutics Stock with 70% Return (vs. 4.3% YTD) [10/7/2025] - Trefis
4 Biotech Stocks Seeing Explosive Momentum GainsAldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Statistical indicators supporting Bicara Therapeutics Inc.’s strengthGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
What drives Bicara Therapeutics Inc stock priceVWAP Trading Strategies & Free Tremendous Portfolio Expansion - earlytimes.in
Is Bicara Therapeutics Inc. stock reversal real or fakeJuly 2025 Trade Ideas & AI Powered Market Entry Ideas - newser.com
Key metrics from Bicara Therapeutics Inc.’s quarterly dataQuarterly Portfolio Summary & Weekly High Potential Alerts - newser.com
Bicara Therapeutics Files $400 Million Mixed Shelf - MarketScreener
Bicara Therapeutics files for mixed shelf offering of up to $400 millionSEC filing - MarketScreener
How to read the order book for Bicara Therapeutics Inc.Fed Meeting & Real-Time Sentiment Analysis - newser.com
Bicara reports positive Phase 1/1b trial results for cancer therapy - MSN
Stifel maintains Buy on Bicara stock with $47 target - MSN
Bicara Therapeutics stock rating reiterated as Buy by TD Cowen - Investing.com South Africa
Bicara Therapeutics stock rating reiterated as Buy by TD Cowen By Investing.com - Investing.com Nigeria
Bicara Therapeutics (NASDAQ:BCAX) Shares Up 5.5%Here's Why - MarketBeat
Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating - TipRanks
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36 - 富途牛牛
What analysts say about Bicara Therapeutics Inc stockTrend Following Strategies & Big Profit Small Investment - earlytimes.in
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bicara Therapeutics Inc Stock (BCAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Raben David | Chief Medical Officer |
Oct 09 '25 |
Sale |
18.45 |
22,000 |
405,900 |
35,497 |
| Hyep Ivan | Chief Financial Officer |
Oct 09 '25 |
Option Exercise |
3.79 |
6,415 |
24,312 |
151,770 |
| Hyep Ivan | Chief Financial Officer |
Oct 09 '25 |
Sale |
18.23 |
6,415 |
116,931 |
145,355 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):